Harefield Hospital
Harefield, Middlesex, UB9 6JH, United Kingdom
NCT Number: NCT01649193
The purpose of this study is to determine the important change in the Short Physical Performance Battery (SPPB) when used in patients with lung disease. The SPPB is a simple physical test that measures balance and the functioning of the legs. It has been widely used in healthy elderly populations and predicts hospital admission and the onset of disability. The SPPB has not previously been used in patients with lung disease, and it is not clear what change in this test is considered meaningful and worthwhile by patients or doctors (the minimal clinically important difference: MID). Knowing what the MID for the SPPB will allow researchers and doctors to evaluate the effectiveness of current and new treatments, and to detect improvement or deterioration in the condition of patients.
Looking for future studies?
Notify MeAll sexes
Observational
Harefield, Middlesex, UB9 6JH, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Royal Brompton & Harefield NHS Foundation Trust
Other
Determining the Minimal Important Difference of the Short Physical Performance Battery and 4m Gait Speed in Chronic Respiratory Disease Patients.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07552779
COVID-19, COVID-19 (Coronavirus Disease 2019)
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial DetailsNCT04657120
Cancer, Cardiovascular Diseases
Antwerp, Belgium
View Trial DetailsNCT06149494
COPD, COPD Exacerbation Acute
London, United Kingdom
View Trial DetailsNCT04170348
Acute Chest Syndrome, Anemia
New York, United States
View Trial Details